HbA1c reflects glycation over roughly two to three months. This tool converts HbA1c to an estimated average glucose and explains general reference ranges. It cannot establish CGM metrics or a personal treatment target.

Why A1C Matters

HbA1c and glucose measurements describe different aspects of glycemia. The ADAG relationship is a population-derived conversion with individual uncertainty. A single HbA1c cannot reveal daily glucose variability, time in range, or meal-specific targets.

UKPDS 35 was an observational analysis in type 2 diabetes. Its associations between lower updated mean HbA1c and fewer complications do not provide an individualized risk curve or guarantee a treatment effect. The 37% microvascular association belongs to UKPDS 35, not DCCT.

Factors That Affect A1C Accuracy

Several medical conditions can cause A1C results to be falsely high or falsely low, independent of actual blood glucose levels. Iron-deficiency anemia prolongs red blood cell survival, which increases glucose attachment time and falsely elevates A1C. Hemolytic anemia and sickle cell trait shorten red blood cell lifespan, reducing the window for glucose attachment and falsely lowering A1C. Recent blood transfusions introduce donor red cells of varying ages and can throw off the measurement in either direction.

Hemoglobin variants — including HbS, HbC, and HbE — are particularly prevalent in individuals of African, Mediterranean, or Southeast Asian ancestry and can interfere with standard immunoassay A1C testing methods. If your A1C results seem inconsistent with your daily glucose readings or your clinical picture, ask your provider about alternative markers such as fructosamine (which reflects a two-to-three-week glucose average) or glycated albumin. These alternatives are not affected by hemoglobin variants and can provide a more reliable picture when A1C is unreliable.

Lowering Your A1C

Changes in nutrition, activity, and prescribed treatment can affect HbA1c. Discuss an individualized target and follow-up interval with your clinician. The goal and scenario panels here show hypothetical HbA1c-to-eAG conversions, not a predicted response to treatment.